The 2009 influenza A (H1N1) virus has reached pandemic level, also affecting the paediatric population. In this context, Health Canada issued an interim approval for the emergency use of oseltamivir in children under one year of age,* given their increased risk for morbidity and mortality from influenza.

Health Canada has commissioned this survey to assess if any serious and life-threatening adverse reactions (ARs)† are occurring with the use of antiviral drugs in Canadian children and youth.

Your contribution is greatly appreciated.

### Over the past month:

1. Have you prescribed the antiviral drugs oseltamivir (Tamiflu™) or zanamivir (Relenza™) to any patients <18 years?  
   Yes ___ No ___  **If no, please proceed to question 3.**
   
   If yes, to how many paediatric patients?
   - oseltamivir: 1–3 ___ 4–6 ___ 7–9 ___ ≥10 ___ approximate number _____
   - zanamivir: 1–3 ___ 4–6 ___ 7–9 ___ ≥10 ___ approximate number _____

2. Have you prescribed oseltamivir (Tamiflu™) to any infants <1 year?  Yes ___ No ___
   
   If yes, to how many?  1 ___ 2 ___ 3 ___ 4 ___ ≥5 ___ approximate number _____

3. Have you seen any serious ARs that you suspect may be related to the use of oseltamivir (Tamiflu™)?  Yes ___ No ___
   
   If yes:
   - In patients <1 year
     - Number of patients 1 ___ 2 ___ 3 ___ 4 ___ ≥5 ___ approximate number _____
     - Number of serious ARs 1 ___ 2 ___ 3 ___ 4 ___ ≥5 ___ approximate number _____
   - List ARs _____________________________________________________________
   
   - List ARs _____________________________________________________________

4. Have you seen any serious ARs that you suspect may be related to the use of zanamivir (Relenza™)?  Yes ___ No ___
   
   If yes:
   - Number of patients 1 ___ 2 ___ 3 ___ 4 ___ ≥5 ___ approximate number _____
   - Number of serious ARs 1 ___ 2 ___ 3 ___ 4 ___ ≥5 ___ approximate number _____
   - List ARs _____________________________________________________________

---


† A serious and life-threatening adverse reaction is one that results in emergency observation, hospitalisation, persistent or significant disability or death.

Please return this survey with your monthly reporting form.  
Thank you for your participation.